NEW YORK (GenomeWeb News) – With the sale of Beckman Coulter to Danaher expected to close later this month, Beckman today disclosed a reshuffling of its management.
In a document filed with the US Securities and Exchange Commission, the Brea, Calif.-based company said that J. Robert Hurley will continue as president and CEO while also assuming responsibilities as interim Diagnostic Division President. Scott Atkin, formerly executive vice president of chemistry, discovery, and instrument systems development, was named president of the Life Science Division, effective June 6.
Following a transition period after the closing of the sale to Danaher, Beckman's Senior Vice President and CFO Charles Slacik's employment will end, Beckman said. Also, the employment of Arnold Pinkston, senior vice president and general counsel, and Robert Kleinert, executive vice president of worldwide commercial operations, will end following the closing of the deal.
At the Jefferies Global Healthcare Conference earlier this week in New York, Danaher CEO Larry Culp said that his firm anticipates its $6.8 billion acquisition of Beckman will close by the end of the month.